-+ 0.00%
-+ 0.00%
-+ 0.00%
Shu Taishen announced that according to the “2026 National Health Insurance Catalogue” issued by the National Health Insurance Administration and the Ministry of Human Resources and Social Security, the company's subsidiary Jiangsu Beijetai Biotechnology Co., Ltd. is included in the “2026 National Health Insurance Catalogue”. The medical insurance classification is Class B, number 59. The indication is bleeding treatment for adult patients with congenital hemophilia A or B with coagulation factor VIII or IX inhibitors > 5 Bethesda units. The “2026 National Health Insurance Catalogue” will be officially implemented on January 1, 2027.
Share
Listen to the news
Shu Taishen announced that according to the “2026 National Health Insurance Catalogue” issued by the National Health Insurance Administration and the Ministry of Human Resources and Social Security, the company's subsidiary Jiangsu Beijetai Biotechnology Co., Ltd. is included in the “2026 National Health Insurance Catalogue”. The medical insurance classification is Class B, number 59. The indication is bleeding treatment for adult patients with congenital hemophilia A or B with coagulation factor VIII or IX inhibitors > 5 Bethesda units. The “2026 National Health Insurance Catalogue” will be officially implemented on January 1, 2027.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending